Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus Ointment for Chronic Allergic Contact Dermatitis
NCT00667056Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2004
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Tacrolimus Ointment 0.1% Iwaki in allergic contact dermatitis (ACD) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Success using the Physician's Global Assessment at 8 Weeks. Started Jul 2004; status: completed.
02
Drugs
Tacrolimus Ointment 0.1% Iwaki
03
Conditions
allergic contact dermatitis (ACD)
Beyond the preview
Go deeper on NCT00667056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667056.